Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.

Sight Sciences, Inc. Common Stock

Vision Biotechnology specializes in developing and manufacturing diagnostic test kits for healthcare professionals to accurately diagnose various diseases. The company incorporates the latest advancements in biotechnology into its products, self-described as elevating healthcare through innovative testing solutions.

Vision Biotechnology

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.

Sight Sciences, Inc.

Sight Sciences develops innovative solutions for ophthalmic surgery, self-described as leading in the field.

Metric
Company Name	Sight Sciences, Inc. Common Stock	Vision Biotechnology
Symbol	SGHT
MSH ID	COM:SIGHTSCIENCES	COM:VISIONBIOTECHNOLOGY
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Medical - Devices	Biotechnology
Country	US	US
Stage
Employee Count	214
Website	sightsciences.com	visionbiotechnology.com
LinkedIn		visionbiotechnolgy
Founders

Metric
Market Cap	202.10M
Enterprise Value
Monthly Web Traffic		434
Web Traffic Growth		1.39
Valuation
Raised Capital

Metric
Revenue	81.06M
Revenue (LTM)
Revenue (NTM)
Gross Profit	69.17M
EBITDA	-56.66M
Operating Income	-57.27M
Net Income	-55.55M
EPS	-1.14
Diluted EPS	-1.14
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.86
Operating Profit Margin	-0.65
EBITDA Margin	-0.70
Net Profit Margin	-0.66
Return on Equity	-0.42
Return on Assets	-0.33
Return on Capital Employed	-0.37

COM:SIGHTSCIENCES

Sight Sciences

Last Close

3.76

22/11 21:00

Market Cap

306.00M

Beta: -

Volume Today

350.82K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-3.29
P/B Ratio	1.60
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	5.03
EV Multiple	-6.90

Metric
Days Sales Outstanding	74.54
Days Payables Outstanding	101.03
Days Inventory Outstanding	241.11
Operating Cycle	311.17
Cash Conversion Cycle	252.28
Asset Turnover	0.53

Metric
Operating Cash Flow	-47.18M
Free Cash Flow	-47.98M
Cash Flow to Debt	-1.04
Operating Cash Flow/Sales	-0.45
Free Cash Flow Yield	-0.28

Metric
Cash & Equivalents	138.13M
Accounts Receivable	661K
Inventory	7.85M
Goodwill
Debt to Capitalization	0.25
Debt to Assets	0.19
Current Ratio	12.11
Quick Ratio	12.44

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.17
R&D to Revenue	0.23
SG&A to Revenue